Discounted Cash Flow
Core Laboratories Inc. /De/
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2021 | $470.3m | $19.7m | $23.0m | 4.2% | $0.43 |
| 2022 | $489.7m (4.1%) | $19.5m (-1.4%) | $14.7m (-36.0%) | 4.0% (-5.3%) | $0.42 (-2.3%) |
| 2023 | $509.8m (4.1%) | $36.7m (88.5%) | $14.2m (-3.6%) | 7.2% (81.1%) | $0.79 (88.1%) |
| 2024 | $523.8m (2.8%) | $31.4m (-14.4%) | $43.4m (205.1%) | 6.0% (-16.7%) | $0.67 (-15.2%) |
| 2025 | $526.5m (0.5%) | $29.7m (-5.5%) | $25.8m (-40.4%) | 5.6% (-6.0%) | $0.64 (-4.5%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.